胰高血糖素样肽-1受体显像检测胰岛素瘤时的 pitfalls
该研究对52例疑似胰岛素瘤患者的前瞻性研究进行事后分析,患者接受⁶⁸Ga-exendin-4 PET/CT和¹¹¹In-exendin-4 SPECT/CT(注射后4和72小时)检查。结果无假阳性,但存在假阴性,原因包括胰十二指肠区域摄取误判、异位胰岛素瘤、小胰岛素瘤、胰岛素瘤与肾脏重叠及胰岛细胞增生症。
要点
- 胰十二指肠区域生理性摄取可被误判为Brunner腺摄取而遗漏胰岛素瘤。
- 小胰岛素瘤、异位胰岛素瘤及与肾脏重叠均可导致GLP-1R显像假阴性。
- 胰岛细胞增生症的存在也是GLP-1R显像的潜在pitfall。
核心结论
- 胰周摄取、胰岛素瘤体积小、胰岛素瘤与肾脏重叠以及胰岛细胞增生症的存在是GLP-1R显像的潜在pitfalls,可导致假性阅读结果。
研究设计与样本
- 对一项前瞻性研究进行事后分析,连续纳入52例患者。
- 所有患者接受1次⁶⁸Ga-exendin-4 PET/CT和2次¹¹¹In-exendin-4 SPECT/CT扫描(注射后4和72小时),随机交叉顺序。
- 3名委员会认证的核医学医师独立阅读所有扫描,对其他结果不知情。
- 参考标准为手术及组织病理学确认胰岛素瘤/胰岛细胞增生症,以及术后血糖水平正常化。
主要发现
- 无假阳性阅读。
- 因胰十二指肠区域摄取误判(误判为Brunner腺生理性摄取而非胰岛素瘤)导致的假阴性:PET/CT 0.6% vs SPECT/CT 9.0%。
- 因异位胰岛素瘤导致的假阴性:PET/CT 0% vs SPECT/CT 2.6%。
- 因小胰岛素瘤导致的假阴性:PET/CT 1.9% vs SPECT/CT 5.1%。
- 因胰岛素瘤与肾脏重叠导致的假阴性:PET/CT 1.9% vs SPECT/CT 4.5%;因胰岛细胞增生症导致的假阴性:PET/CT 0.6% vs SPECT/CT 1.9%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Physiological pancreaticoduodenal uptake of radiolabeled exendin-4 in Brunner glands of the proximal duodenum is the most common pitfall for false interpretation of glucagon-like peptide-1 receptor (GLP-1R) imaging. The aim of this study was to analyze the pancreaticoduodenal uptake in GLP-1R PET/CT and SPECT/CT images and to identify additional potential reading pitfalls in patients with suspected insulinoma. METHODS: A post hoc analysis of a prospective study, including 52 consecutive patients, was performed. All patients underwent 1 Ga-exendin-4 PET/CT and 2 In-exendin-4 SPECT/CT scans (4 and 72 hours postinjection) in a randomized crossover order. Three board-certified nuclear medicine physicians read all scans independently. They were unaware of other results. Reference standard was surgery with histopathological confirmation of an insulinoma/nesidioblastosis and normalization of blood glucose levels after surgery. RESULTS: There were no false-positive readings. However, there were a number of false-negative PET/CT and SPECT/CT readings, respectively: (1) due to false interpretation of uptake in the pancreaticoduodenal region (falsely interpreted as physiological uptake in Brunner glands instead of an insulinoma in 0.6% vs 9.0%), (2) due to ectopic insulinoma (0% vs 2.6%), (3) due to small insulinoma (1.9% vs 5.1%), (4) due to insulinoma overlap with kidneys (1.9% vs 4.5%), and (5) due to nesidioblastosis (0.6% and 1.9%). Pitfalls were identified in all GLP-1R PET/CT and SPECT/CT scans. CONCLUSIONS: Peripancreatic uptake, small size of an insulinoma, insulinoma overlap with kidneys, and presence of nesidioblastosis are potential pitfalls in GLP-1R imaging, which can lead to false reading results.
引用
- Antwi K, Hepprich M, Müller NA, et al. Pitfalls in the Detection of Insulinomas With Glucagon-Like Peptide-1 Receptor Imaging. Clin Nucl Med. 2020. PMID: 32558709. doi:10.1097/RLU.0000000000003124
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。